Related Experiment Video

Updated: Mar 24, 2026

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

14.7K

STARD13-correlated ceRNA network inhibits EMT and metastasis of breast cancer

Xiaoman Li1,2, Lufeng Zheng1,2, Feng Zhang1,2

  • 1School of Life Science and Technology, China Pharmaceutical University, Nanjing, People's Republic of China.

Oncotarget
|March 18, 2016
PubMed

Insights

The study identifies CDH5, HOXD1, and HOXD10 as competing endogenous RNAs (ceRNAs) that suppress breast cancer metastasis by interacting with STARD13. Higher levels of these ceRNAs correlate with improved patient survival.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Competing endogenous RNAs (ceRNAs) play a role in cancer initiation and progression.
  • Understanding ceRNA networks is crucial for developing novel cancer therapies.

Purpose of the Study:

  • To identify novel ceRNAs involved in breast cancer metastasis.
  • To elucidate the mechanism by which these ceRNAs regulate metastasis.
  • To assess the prognostic value of these ceRNAs in breast cancer patients.

Main Methods:

  • Identification of STARD13 ceRNAs using expression profiling in breast cancer cell lines and tissues.
  • In vitro and in vivo experiments to assess the role of identified ceRNAs in epithelial-mesenchymal transition (EMT) and metastasis.
  • Kaplan-Meier survival analysis to correlate ceRNA expression with patient survival.

Main Results:

  • CDH5, HOXD1, and HOXD10 were identified as putative STARD13 ceRNAs, showing concordant expression patterns with STARD13 in breast cancer.
  • The 3'UTRs of CDH5, HOXD1, and HOXD10 were found to suppress breast cancer metastasis by inhibiting EMT, mediated by crosstalk with STARD13.
  • High mRNA levels of STARD13 and its identified ceRNAs were significantly associated with better survival outcomes in breast cancer patients.

Conclusions:

  • CDH5, HOXD1, and HOXD10 function as STARD13 ceRNAs, inhibiting breast cancer metastasis through EMT suppression.
  • The STARD13-ceRNA network involving CDH5, HOXD1, and HOXD10 holds potential as a prognostic biomarker for breast cancer.
  • Targeting this ceRNA network could offer a therapeutic strategy for reducing breast cancer metastasis.
Keywords:
3′UTRsEMTSTARD13breast cancer metastasisceRNA

More Related Videos

The Use of Mouse Mammary Tumor Cells in an In Vitro Invasion Assay as a Measure of Oncogenic Cell Behavior08:12

The Use of Mouse Mammary Tumor Cells in an In Vitro Invasion Assay as a Measure of Oncogenic Cell Behavior

Published on: June 12, 2019

5.5K
Induction and Analysis of Epithelial to Mesenchymal Transition10:37

Induction and Analysis of Epithelial to Mesenchymal Transition

Published on: August 27, 2013

36.7K

Related Concept Videos

Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
6.8K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.4K
Cadherins in Tissue Organization01:19

Cadherins in Tissue Organization

The cadherins are a superfamily of cell adhesion molecules comprising over 180 variants, with specific tissues expressing a particular combination of cadherin types. Cadherins generally exhibit homophilic binding; i.e., cadherins on one cell bind to cadherins of the same or closely related type on another cell. Thus, cells of the same type have a specific affinity to bind to each other and sort themselves into clusters to form tissues.
Cell Sorting During Development
Cell sorting plays an...
4.5K
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
8.1K
Cancer Cell Migration through Invadopodia01:35

Cancer Cell Migration through Invadopodia

Invadosome is a broad category of cell surface structures with proteolytic activity that  degrades the extracellular matrix (ECM). Invadosomes are present in normal cell types, including macrophages, endothelial cells, and neurons, as well as tumor cells. Although the macrophage podosomes and tumor cell invadopodia are classified as invadosomes, they have different structures, molecular pathways, and functions. Podosomes are short structures that last for a few minutes. However,...
3.5K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K